Naratriptan + DihydroergotamineContraindicated
Ergot-type medication causing prolonged vasospastic reactions with additive effects when used with naratriptan. Contraindicated within 24 hours of each other.
Source: NLP:naratriptan
Naratriptan Interactions
Brand names: Naratriptan
Route: Oral
Contraindications
4 CONTRAINDICATIONS Naratriptan tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions (5.1) ] Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2) ] History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke [see Warnings and Precautions (5.4) ] Peripheral vascular disease [see Warnings and Precautions (5.5) ] Ischemic bowel disease [see Warnings and Precautions (5.5) ] Uncontrolled hypertension [see Warnings and Precautions (5.8) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.2 )] Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9) ] Severe renal or hepatic impairment [see Use in Specific Populations ( 8.6 , 8.7 ), Clinical Pharmacology (12.3) ] History of coronary artery disease or coronary artery vasospasm ( 4 ) Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 ) History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( 4 ) Peripheral vascular disease ( 4 ) Ischemic bowel disease ( 4 ) Uncontrolled hypertension ( 4 ) Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan) or an ergotamine-containing medication ( 4 ) Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) ( 4 ) Severe renal or hepatic impairment ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are no adequate data on the developmental risk associated with use of naratriptan in pregnant women. Data from a prospective pregnancy exposure registry and epidemiological studies of pregnant women have documented outcomes in women exposed to naratriptan during pregnancy; however, due to small sample sizes, no definitive conclusions can be drawn regarding the risk of birth defects following exposure to naratriptan [ see Data ]. In animal studies, naratriptan produced developmental toxicity (including embryolethality and fetal abnormalities) when administered to pregnant rats and rabbits. The lowest doses producing evidence of developmental toxicity in animals were associated with plasma exposures 2.5 (rabbit) to 11 (rat) times that in humans at the maximum recommended daily dose (MRDD) [ see Data ]. In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The reported rate of major birth defects among deliveries to women with migraine ranged from 2.2% to 2.9% and of miscarriage was 17%, which were similar to rates reported in women without migraine. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Several studies have suggested that women with migraine may be at increased risk of preeclampsia during pregnancy. Data Human Data : The numbers of exposed pregnancy outcomes accumulated during the Sumatriptan/Naratriptan/ Treximet® (sumatriptan and naproxen sodium) Pregnancy Registry, a population-based international prospective study that collected data from October 1997 to September 2012, and smaller observational studies, were insufficient to define a level of risk for naratriptan in pregnant women. The Registry documented outcomes of 57 infants and fetuses exposed to naratriptan during pregnancy (52 exposed during the first trimester and 5 exposed during the second trimester). The oc
6 interactions on record
Naratriptan + ErgotamineContraindicated
Ergotamine-containing drugs cause prolonged vasospastic reactions that may be additive with naratriptan. Use within 24 hours of each other is contraindicated.
Source: NLP:naratriptan
Naratriptan + MethysergideContraindicated
Ergot-type medication causing prolonged vasospastic reactions with additive effects when used with naratriptan. Contraindicated within 24 hours of each other.
Source: NLP:naratriptan
Naratriptan + TriptansContraindicated
Other 5-HT1B/1D agonists (triptans) contraindicated within 24 hours of naratriptan due to risk of additive vasospastic reactions.
Source: NLP:naratriptan
Cases of serotonin syndrome reported with co-administration of triptans and MAO inhibitors. Risk of serious serotonergic adverse effects.
Source: NLP:naratriptan
Naratriptan + TcasMajor
Cases of serotonin syndrome reported with co-administration of triptans and tricyclic antidepressants. Risk of serious serotonergic adverse effects.
Source: NLP:naratriptan